Hmmm...an interesting theory: If Longhauler result
Post# of 155320
(Total Views: 654)
Posted On: 06/17/2021 1:58:37 AM
Hmmm...an interesting theory: If Longhauler results were good, they would have been released.
And the corollary follows that since the results were not released then we know the long hauler phase 2 trial results to be announced on Monday are poor.
Well, that's an interesting prediction and we'll see if its correct on Monday.
However, by at least two objective measurements, the long hauler trial results have already been reported and those results were not good and they were not great. They were FANTASTIC.
Of course those objective measurements are the at least two patients who could barely walk in and who left the trial feeling great with a bounce in their step.
While these results are unquestionably fantastic, the overall trial result may not be sufficiently statistically significant to warrant approval.
And this is the real challenge that Cytodyn faces.
How can patients who are responsive to leronlimab be identified?
We already know with practically 100% certainty that leronlimab works very effectively for certain critical covid patients. The UK patient who was on ECMO for months and then off three days after leronlimab proves that leronlimab works sometimes.
The problem with CD12 was that it didn't work for everyone. Is that because the age skew was off? Is that because leronlimab is much more effective in critical patients? Is that because the dose was high enough or sustained for a sufficient period of time? Hopefully the Brazil trial will answer these questions.
The same types of questions will arise in the long haulers phase 3 trial.
Has Cytodyn gotten enough information from phase 2 to select phase 3 endpoints for specific patient populations that will succeed?
Hopefully Monday will bring a thoughtfull analysis of what has been learned on phase 2 and why phase 3 will succeed. Its about time Cytodyn executed something, anything, without looking like a bunch of blithering idiots.
And the corollary follows that since the results were not released then we know the long hauler phase 2 trial results to be announced on Monday are poor.
Well, that's an interesting prediction and we'll see if its correct on Monday.
However, by at least two objective measurements, the long hauler trial results have already been reported and those results were not good and they were not great. They were FANTASTIC.
Of course those objective measurements are the at least two patients who could barely walk in and who left the trial feeling great with a bounce in their step.
While these results are unquestionably fantastic, the overall trial result may not be sufficiently statistically significant to warrant approval.
And this is the real challenge that Cytodyn faces.
How can patients who are responsive to leronlimab be identified?
We already know with practically 100% certainty that leronlimab works very effectively for certain critical covid patients. The UK patient who was on ECMO for months and then off three days after leronlimab proves that leronlimab works sometimes.
The problem with CD12 was that it didn't work for everyone. Is that because the age skew was off? Is that because leronlimab is much more effective in critical patients? Is that because the dose was high enough or sustained for a sufficient period of time? Hopefully the Brazil trial will answer these questions.
The same types of questions will arise in the long haulers phase 3 trial.
Has Cytodyn gotten enough information from phase 2 to select phase 3 endpoints for specific patient populations that will succeed?
Hopefully Monday will bring a thoughtfull analysis of what has been learned on phase 2 and why phase 3 will succeed. Its about time Cytodyn executed something, anything, without looking like a bunch of blithering idiots.
(16)
(0)